In this study, TRPM2 elevation was detected in close to 60% of EGFRm NSCLC tissues from patients whose disease relapsed from treatment with EGFR‐TKIs including osimertinib. The gene discussed is TRPM2; the disease is non-small cell lung carcinoma.